Currently funded projects for which Dr. Raskind is Principal Investigator include:
Alzheimer's Disease Research Center (M. Raskind, Director): Core A, Administration The major goals of this project are to: (l) integrate, coordinate, and oversee the scientific projects of the ADRC and (2) provide fiscal and logistical management for the ADRC.

Psychopathology of Alzheimer's: APOE and the HPA Axis: The major goals of this project are to determine the effect of APOE genotype on CSF cortisol concentrations in persons with AD, nondemented older persons, and young and middle-aged persons; to determine the effect of the APOE-?4 allele on the plasma cortisol response to exogenous adrenocorticotrophic hormone; to determine the effect of CSF cortisol concentrations in cognitive decline and on incidence of mild cognitive impairment and probable AD among nondemented older persons with the APOE-?4 allele followed longitudinally.

Alzheimer's Disease and Aging: Psychoneuroendocrinology: To determine the effects of AD and human aging (the major risk factor for AD) on two classic stress-responsive neuroendocrine systems: the sympathetic nervous system (SNS) and the hypothalamic-pituitary-adrenocortical (HPA) axis.

Murray Raskind is currently Professor and Vice-Chair in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine, Director of the University of Washington Alzheimer's Disease Research Center, Director of the VISN 20 Northwest Network VA Puget Sound Health Care System Mental Illness Research, Education and Clinical Center and Director, Mental Health Service, VA Puget Sound Health Care System, Seattle, Washington.

Selected Relevant Publications
Tsuang D, Raskind MA, Leverenz J, Peskind ER, Schellenberg GD, Bird TD. The effect of apolipoprotein E genotype on expression of an autosomal dominant schizophreniform disorder with progressive dementia and neurofibrillary tangles. Biol Psychiatry 41:191-195, 1997.

Raskind MA, Peskind ER. Neurotransmitter abnormalities and the psychopharmacology of Alzheimer’s disease. In: Progress in Alzheimer’s Disease and Similar Conditions, LL Heston, ed. pp 245-257. American Psychiatric Press, Washington, DC, 1997.

Raskind MA. Psychopharmacology of noncognitive abnormal behaviors in Alzheimer's disease. J Clin Psychiatry 59(Suppl 9):28-32, 1998.

Raskind MA. The clinical interface of depression and dementia. J Clin Psychiatry 59:9-12, 1998.

Craft S, Asthana S, Schellenberg GD, Cherrier M, Baker LD, Newcomer J, Plymate S, Latendresse S, Petrova A, Lofgreen C, Grimwood K, Raskind M, Peskind E. Insulin metabolism in Alzheimer’s disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 70:146-152, 1999.

Craft S, Asthana S, Schellenberg G, Baker L, Cherrier M, Boyt AA, Martins RN, Raskind M, Peskind E, Plymate S. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann NY Acad Sci 903:222-228, 2000.

Pascualy M, Petrie EC, Brodkin K, Peskind ER, Wilkinson CW, Raskind MA. Hypothalamic pituitary adrenocortical and sympathetic nervous system responses to the cold pressor test in Alzheimer's disease. Biol Psychiatry 48:247-254, 2000.

Petrie EC, Peskind ER, Dobie DJ, Veith RC, Raskind MA. Plasma catecholamine and cardiovascular responses to physostigmine in Alzheimer's disease and aging. Psychoneuroendocrinology 26:147-164, 2001.